More compounds, more uncertainty
A “stack” combines compounds. Evidence for each ingredient does not prove the combination works or is safe.
UNDERSTAND WHAT CHANGED
A “stack” combines compounds. Evidence for each ingredient does not prove the combination works or is safe.
Record dates, symptoms, sleep, appetite, activity, and medication changes. If tracking weight or waist size, use consistent conditions and look at trends.
Share the exact product, ingredients, batch, other medicines and supplements, and any new symptoms. Personal observations cannot establish cause or replace clinical evaluation.
For educational purposes only. Not medical advice, diagnosis, treatment, or prescribing guidance. Research and regulatory information can change over time.
BEFORE ANY STACK
Pick one focus at a time: fat loss, muscle, healing, or optimization.
1–2 compounds per protocol, and rarely more than 3. Each addition multiplies uncertainty and makes side effects harder to trace.
Never combine two GLP-1-based compounds. They act on overlapping receptors.
On/off schedules seen online (like “8–12 weeks on, 4–6 off”) come from community convention, not controlled trials. Non-approved peptides have no studied duration. Approved GLP-1 medicines were studied as long-term treatments, and weight often returns after stopping.
Baseline bloodwork, then rechecks every 8–12 weeks: IGF-1, fasting glucose and HbA1c, lipids, liver enzymes, CBC/CMP, and CRP.
Protein, resistance training, sleep, and hydration drive most results. No stack replaces them.
Blends hide repeats. KLOW already contains BPC-157, TB-500, GHK-Cu, and KPV. A CagriSema-style vial already contains semaglutide. Adding a separate vial of any ingredient doubles it, and copper from GHK-Cu and AHK-Cu adds up. Blend math
A pre-mixed blend fixes the ratio between its ingredients. Changing the amount of one changes all of them. If a plan calls for different amounts of each, a single blend can’t match it.
STACK LIBRARY
How each popular combination is described, what it contains, typical lengths discussed, and what the evidence actually covers. Doses are not listed.
Aggressive fat loss or obesity — GLP-1 + GIP + glucagon in one molecule.
Retatrutide alone (triple agonist).
Why it is combinedHits appetite, insulin response, and energy expenditure at once, so it is often listed as a stand-alone “stack.”
Length studiedTrials ran 48–104 weeks, and weight is often regained after stopping.
EvidenceUp to 24.2% (Phase 2, 48 weeks) and 28.3% (Phase 3, 80 weeks) average weight loss. Not FDA approved.
CautionsGI side effects, gallbladder and pancreatitis risk, and the thyroid boxed warning. Only one GLP-1-based compound at a time; protein intake and resistance training help protect muscle.
Metabolic syndrome, insulin resistance, steady fat loss.
Tirzepatide alone (GLP-1 + GIP dual agonist).
Why it is combinedTwo incretin signals improve glucose control and appetite together.
Length studiedStudied as a long-term treatment.
EvidenceUp to 20.9% at 72 weeks (SURMOUNT-1); about 25% total at 88 weeks for people who stayed on it (SURMOUNT-4).
CautionsGI side effects, gallbladder and pancreatitis risk, and the thyroid boxed warning. Only one GLP-1-based compound at a time; protein intake and resistance training help protect muscle.
General fat loss and appetite control; the most established option.
Semaglutide alone (GLP-1 agonist).
Why it is combinedSuppresses hunger and slows stomach emptying; the longest safety record of the three.
Length studiedStudied as a long-term treatment.
EvidenceAbout 15% average weight loss at 68 weeks (STEP 1) and 15.2% at 104 weeks (STEP 5).
CautionsGI side effects, gallbladder and pancreatitis risk, and the thyroid boxed warning. Only one GLP-1-based compound at a time; protein intake and resistance training help protect muscle.
A simpler, lower-cost combination: appetite control plus a fat-breakdown fragment.
Semaglutide (appetite and glucose) + AOD-9604 (GH fragment aimed at fat breakdown).
Why it is combinedPairs a proven appetite medicine with a compound marketed for fat breakdown without raising IGF-1.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceSemaglutide has strong human evidence; AOD-9604 failed its larger human trial. Each ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsGI side effects, gallbladder and pancreatitis risk, and the thyroid boxed warning. Only one GLP-1-based compound at a time; protein intake and resistance training help protect muscle.
Belly-fat reduction while holding on to muscle.
Tesamorelin (GHRH analog) + Ipamorelin (ghrelin-receptor agonist).
Why it is combinedTwo different GH-release signals, aimed at visceral fat loss with lean-mass retention during a cut or recomp.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceTesamorelin reduced visceral fat about 15% over 26 weeks in its approved HIV-lipodystrophy population. Each ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsWater retention, increased hunger, tingling, and possible changes in blood sugar. IGF-1 and glucose are the markers usually watched. Not appropriate with active cancer.
Midsection fat loss with body recomposition.
Tesamorelin (GH release, visceral fat) + AOD-9604 (fat-breakdown fragment).
Why it is combinedCombines a visceral-fat-focused GH signal with a lipolysis-focused fragment.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsWater retention, increased hunger, tingling, and possible changes in blood sugar. IGF-1 and glucose are the markers usually watched. Not appropriate with active cancer.
Stubborn areas like belly, love handles, or thighs; often paired with fasted cardio.
AOD-9604 (fat-breakdown fragment) + CJC-1295 (GHRH analog).
Why it is combinedAims to raise fat breakdown and GH output without raising blood sugar.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceThe 2.8 kg vs 0.8 kg figure often quoted is from a single early AOD-9604 trial, not this stack. Each ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsWater retention, increased hunger, tingling, and possible changes in blood sugar. IGF-1 and glucose are the markers usually watched. Not appropriate with active cancer.
Metabolic plateaus and stubborn fat.
5-Amino-1MQ (NNMT inhibitor, small molecule) + MOTS-c (mitochondrial peptide).
Why it is combinedBoth target cellular energy use: NAD+ levels and mitochondrial efficiency.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceBoth compounds are supported mainly by animal studies (about 5% weight reduction in mice for 5-Amino-1MQ). Each ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsFatigue, headaches, dry mouth, and nausea are reported. Human safety data is very limited.
Weight retention linked to gut inflammation or bloating.
KPV (anti-inflammatory) + BPC-157 (gut-lining repair).
Why it is combinedThe idea is indirect: lowering inflammation may support fat loss. Neither compound directly causes weight loss.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsNo large human safety data for these compounds. Injection-site reactions and fatigue are reported. Not appropriate for anyone with active cancer.
The foundational GH stack: steady GH and IGF-1 support, sleep, and recovery.
CJC-1295 with DAC (GHRH analog) + Ipamorelin (ghrelin-receptor agonist). A pre-bed-only version is marketed for sleep and recovery.
Why it is combinedA GHRH signal plus a ghrelin signal produce a larger GH pulse than either alone.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsWater retention, increased hunger, tingling, and possible changes in blood sugar. IGF-1 and glucose are the markers usually watched. Not appropriate with active cancer.
Longer-term GH support that follows the natural rhythm more closely.
Sermorelin (short-acting GHRH) + Ipamorelin.
Why it is combinedShort pulses are thought to reduce desensitization compared with long-acting analogs.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceSermorelin was once FDA approved for children with GH deficiency; adult use is not established. Each ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsWater retention, increased hunger, tingling, and possible changes in blood sugar. IGF-1 and glucose are the markers usually watched. Not appropriate with active cancer.
For people struggling to eat enough to gain size.
GHRP-6 (ghrelin mimetic with strong hunger effect) + a GHRH analog.
Why it is combinedStrong GH pulse plus a large appetite increase.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsIntense hunger, water retention, fatigue, and possible prolactin and cortisol rises. Prohibited in tested sport.
Advanced anabolic stack: direct muscle signaling plus GH support.
IGF-1 LR3 (long-acting IGF-1 analog) + CJC-1295 + Ipamorelin.
Why it is combinedPairs direct IGF-1 action on muscle with increased natural GH output.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceIGF-1 LR3 has no published human trials. Each ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsLow blood sugar (hypoglycemia) is a key risk with IGF-1 LR3. Not appropriate for anyone with a cancer history. Water retention, increased hunger, tingling, and possible changes in blood sugar. IGF-1 and glucose are the markers usually watched. Not appropriate with active cancer.
Lean gains with less water retention.
IGF-1 LR3 + GHRP-2 + Mod GRF 1-29 (CJC-1295 without DAC).
Why it is combinedStronger short GH pulses plus direct IGF-1 signaling.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsHypoglycemia risk, prolactin and cortisol rises with GHRP-2, and the cancer caution for IGF-1 LR3. Prohibited in tested sport.
Muscle, tendon, and ligament injuries.
BPC-157 (local repair) + TB-500 (whole-body recovery).
Why it is combinedOne is discussed for the injury site and the other for systemic repair, so they are paired for faster healing and mobility.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsNo large human safety data for these compounds. Injection-site reactions and fatigue are reported. Not appropriate for anyone with active cancer.
Post-surgery healing, scarring, and post-op fatigue.
TB-500 (tissue repair) + LL-37 (antimicrobial) + GHK-Cu (collagen and skin).
Why it is combinedCovers repair, infection defense, and skin and connective-tissue remodeling.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsNo large human safety data for these compounds. Injection-site reactions and fatigue are reported. Not appropriate for anyone with active cancer. Surgical recovery should be managed with the surgical team.
Skin and tendon recovery, soft-tissue strain.
GHK-Cu (collagen, antioxidant) + BPC-157 (tissue repair).
Why it is combinedPairs a collagen-focused peptide with a soft-tissue repair peptide.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsNo large human safety data for these compounds. Injection-site reactions and fatigue are reported. Not appropriate for anyone with active cancer.
Gut inflammation alongside joint pain.
BPC-157 (gut and tissue repair) + KPV (anti-inflammatory) + TB-500 (systemic recovery).
Why it is combinedTargets the proposed link between gut inflammation and whole-body joint pain.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsNo large human safety data for these compounds. Injection-site reactions and fatigue are reported. Not appropriate for anyone with active cancer.
Autoimmune-type pain and joint inflammation with a gut link.
KPV + BPC-157 + Thymosin Alpha-1 (immune modulator).
Why it is combinedCombines inflammation control, tissue repair, and immune balancing.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsNo large human safety data for these compounds. Injection-site reactions and fatigue are reported. Not appropriate for anyone with active cancer. Autoimmune conditions need medical care; immune-active peptides can cause flu-like symptoms.
Concussion-type recovery, burnout, and chronic fatigue.
Semax (BDNF, focus) + Epitalon (sleep and circadian rhythm) + BPC-157.
Why it is combinedAims at brain recovery, sleep quality, and general repair together.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsNasal irritation and overstimulation with Semax. Head injuries need medical evaluation first.
Overtraining, low energy, and poor recovery markers like low HRV.
Epitalon (sleep) + TB-500 (repair) + optional MOTS-c (mitochondrial energy).
Why it is combinedCombines sleep support, tissue repair, and cellular energy.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsNo large human safety data for these compounds. Injection-site reactions and fatigue are reported. Not appropriate for anyone with active cancer.
Gut-lining support, bloating, and food sensitivities.
BPC-157 (gut-lining repair) + KPV (anti-inflammatory).
Why it is combinedThe most common gut pairing: repair plus inflammation control.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceBoth are supported mainly by animal gut-inflammation models. Each ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsNo large human safety data for these compounds. Injection-site reactions and fatigue are reported. Not appropriate for anyone with active cancer.
Marketed for colitis or Crohn’s-type inflammation.
BPC-157 + KPV + LL-37 (antimicrobial).
Why it is combinedAdds microbial defense to repair and inflammation control.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsUlcerative colitis and Crohn’s disease are serious conditions that need a gastroenterologist; these peptides are not treatments for them. LL-37 can trigger immune activation.
Gut imbalance after antibiotics or illness, often with probiotics.
LL-37 + BPC-157, with probiotics as support.
Why it is combinedPairs microbial balance with mucosal repair.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsFlu-like symptoms from LL-37 and caution for anyone prone to autoimmunity.
Gut issues tied to stress, low energy, and fatigue.
MOTS-c (mitochondrial) + BPC-157 + KPV.
Why it is combinedAdds cellular-energy support to gut repair and inflammation control.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsNo large human safety data for these compounds. Injection-site reactions and fatigue are reported. Not appropriate for anyone with active cancer.
Immune reset for chronic infections or fatigue.
Thymosin Alpha-1 (immune modulator) + KPV + BPC-157.
Why it is combinedCombines immune balancing, inflammation control, and gut repair.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceThymosin Alpha-1 is approved outside the U.S. for specific uses. Each ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsTemporary fatigue and body aches from immune activation. Ongoing infections need medical care.
Full-body inflammation with gut involvement.
KPV (anti-inflammatory) + Thymosin Alpha-1 (immune modulator).
Why it is combinedPairs cytokine control with T-cell regulation.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsTemporary fatigue or flu-like aches.
Frequent illness and post-viral recovery.
Thymosin Alpha-1 + LL-37 (antimicrobial) + KPV.
Why it is combinedCombines immune balancing, pathogen defense, and inflammation control.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsImmune activation symptoms; LL-37 is not for long-term use and needs caution with autoimmunity.
Immune support with a gut and mitochondrial angle.
Thymosin Alpha-1 + MOTS-c + BPC-157.
Why it is combinedPairs immune balancing with cellular energy and gut repair.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsTemporary fatigue and immune activation symptoms.
Gut issues with low immunity and poor recovery.
BPC-157 + LL-37 + Epitalon (sleep and circadian rhythm).
Why it is combinedCombines gut repair, host defense, and sleep support.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsNo large human safety data for these compounds. Injection-site reactions and fatigue are reported. Not appropriate for anyone with active cancer.
Cellular-aging research: telomeres, DNA repair, and metabolic resilience.
Epitalon (telomerase, melatonin) + MOTS-c (mitochondrial energy).
Why it is combinedPairs two of the most discussed “longevity” peptides.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceAnti-aging effects are unproven in people. Each ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsGenerally reported as mild; fatigue and sleep changes are possible.
Experimental senescent-cell clearance.
FOXO4-DRI (senescent-cell clearance) + Epitalon.
Why it is combinedAims to clear aged cells and support DNA repair together.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceFOXO4-DRI has only mouse and lab data. Each ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsLong-term safety is unknown. Highly experimental.
Memory, focus, and brain fog; sometimes with BPC-157 added.
Dihexa (synapse formation, animal data) + Semax (BDNF), optional BPC-157.
Why it is combinedPairs two compounds studied for neuroplasticity.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceDihexa has no human trials. Each ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsOverstimulation and anxiety. Dihexa acts on a pathway also linked to cancer growth, a theoretical long-term risk.
Stress, anxiety, and poor sleep.
Selank (calming, GABA) + Semax (focus) + Epitalon (sleep rhythm).
Why it is combinedBalances calm and focus while supporting sleep cycles.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceSelank and Semax are approved only in Russia. Each ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsNasal irritation; overstimulation with stimulants. Anxiety and insomnia deserve medical evaluation.
Energy, focus, and immune support for demanding schedules.
MOTS-c + Dihexa + Thymosin Alpha-1.
Why it is combinedCombines cellular energy, cognition, and immune support.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceEach ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsOverstimulation, fatigue, and immune activation symptoms; Dihexa lacks human safety data.
Brain recovery after injury, used in clinics abroad.
Cerebrolysin (a pig-brain-derived peptide mixture) + Semax.
Why it is combinedPairs two compounds studied for neuroprotection.
LengthNo studied duration. This combination hasn’t been tested in controlled human trials, so any length you see online is convention, not evidence.
EvidenceCerebrolysin is approved in some countries for stroke and brain injury, with mixed trial results; not approved in the U.S. Each ingredient has its own evidence level (see the Compound Library). This combination has not been tested in controlled human trials.
CautionsGiven by injection or IV in clinics; dizziness and allergic reactions are possible. Brain injury needs medical care.
* Approval applies to specific branded products and indications only. “Combo not studied” means no controlled human trial has tested that combination; see the Compound Library for each ingredient’s evidence. Lengths are those discussed in common peptide guides, not medical recommendations. For educational purposes only. Not medical advice, diagnosis, treatment, or prescribing guidance.